🇺🇸 FDA
Patent

US 10022347

Compositions and methods for diagnosis and treatment of metabolic syndrome

granted A61KA61K31/20

Quick answer

US patent 10022347 (Compositions and methods for diagnosis and treatment of metabolic syndrome) held by United States of America as represented by the Secretary of the Air Force expires Mon Jul 12 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
United States of America as represented by the Secretary of the Air Force
Grant date
Tue Jul 17 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 12 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
7
CPC classes
A61K, A61K31/20